Peptide Research Collection Library
Explore the compound
Quick Facts
Mechanism of Action
Formulation: This premixed research formulation contains Cagrilintide 2.5 mg, Semaglutide 2.5 mg.
Evidence context: Evidence for individual components and evidence for the combined formulation are tracked separately; findings for one component should not be assumed to establish effects for the mixture.
- Promotes clinically meaningful weight reduction and waist-size improvement in obesity research [1].
- Improves blood-glucose control and A1C outcomes in type 2 diabetes studies [1].
- Supports appetite control and reduced caloric intake through GLP-1 receptor activity [3].
- Associated with cardiometabolic improvements including blood pressure, lipids, and inflammation markers in large clinical programs [1].
- Has official clinical-trial and NIH-indexed evidence across diabetes, obesity, and cardiovascular-risk research [1][2].
Blend Composition
Listed ingredient quantities represent the contents of the full vial, not an amount to administer. This formulation is supplied as a liquid; no reconstitution is needed.
| Ingredient | Listed quantity per vial |
|---|---|
| Cagrilintide | 2.5 mg |
| Semaglutide | 2.5 mg |
Research Applications & Context
Community-reported protocol schedules.
Research Dosage Information
Reported research quantities and their source context. These are not recommendations, and source status varies.
Scroll the table horizontally to read every column. Select a row to inspect it in the calculator.
Weeks 1-4: 500 mcg Once weekly. Weeks 1-4. Weeks 5-8: 1000 mcg Once weekly. Weeks 5-8. Weeks 9-12: 2000 mcg Once weekly. Weeks 9-12. Weeks 13-16: 3400 mcg Once weekly. Weeks 13-16. Week 17+: 4800 mcg Once weekly. Week 17+.
| Phase | Reported Amount | Frequency | Draw Units | Cycle | Notes | Calculator |
|---|---|---|---|---|---|---|
| Weeks 1-4 | 500 mcg | Once weekly | Select a vial | Weeks 1-4 | Community-reported protocol. Source quantity: 250mcg per component; 2 components combined. | |
| Weeks 5-8 | 1000 mcg | Once weekly | Select a vial | Weeks 5-8 | Community-reported protocol. Source quantity: 500mcg per component; 2 components combined. | |
| Weeks 9-12 | 2000 mcg | Once weekly | Select a vial | Weeks 9-12 | Community-reported protocol. Source quantity: 1000mcg per component; 2 components combined. | |
| Weeks 13-16 | 3400 mcg | Once weekly | Select a vial | Weeks 13-16 | Community-reported protocol. Source quantity: 1700mcg per component; 2 components combined. | |
| Week 17+ | 4800 mcg | Once weekly | Select a vial | Week 17+ | Community-reported protocol. Source quantity: 2400mcg per component; 2 components combined. |
Dosing Protocol & Schedule
Community-reported research schedules, not clinically validated protocols. Select a reported scenario and duration to calculate mathematical quantities.
| Period | Research Dose | Frequency | Total Injections | Total amount | Volume per entry | U-100 equivalent |
|---|
Strength changes affect volume and supplies, not the underlying community-reported quantities. Figures exceeding the selected syringe capacity are flagged; they are not instructions for splitting administrations.
Plan a Regimen Schedule
Save the selected research protocol to your private calendar. Scheduled entries never create Dose Logs.
Reconstitution Calculator
Select the vial strength you are examining. The reference chart displays examples, not recommended preparation volumes or validated protocols.
Reconstitution Reference Chart
Hypothetical volume comparisons for the selected vial. No particular volume is endorsed, and vial capacity, solubility, excipients and product-specific instructions are not established by this table.
| Example volume | Calculated concentration | Calculator |
|---|---|---|
| 1 mL | — | |
| 2 mL | — | |
| 3 mL | — | |
| 4 mL | — | |
| 5 mL | — |
Choose a compatible dry vial to see reference concentrations.
Research-only mathematical comparisons; not instructions to compound, prepare, or administer peptides. Community-reported protocols are not clinically validated by inclusion here.
Supplies Needed — Estimate
Select a vial strength and an example reconstitution volume below. Counts use only the checked, computable rows above; they are not product-specific sterility, compatibility, or stability guidance.
Select a compatible vial and volume below to view quantities.
Educational and entertainment purposes only. Research use only; not for human or animal administration. Pad counts assume two per Total entry; syringe counts include additional containers where a single entry exceeds the selected syringe capacity. Vial totals assume full theoretical recovery and do not account for dead volume, spoilage, asepsis, expiration, potency, route, or beyond-use dating. These figures are not a recommended supplies list for an actual procedure.
Published References (0 identified)
A recorded identifier identifies a publication; it does not establish that its claims have been independently verified.
Research indexes & other source links
Searches, registries and unverified source records are discovery resources, not verified published studies.
- PubMed.gov biomedical literature: Cagrilintide + Semaglutide View source ↗ PubMed index/search · Source link recorded; claim verification separate
- ClinicalTrials.gov study registry: Cagrilintide + Semaglutide View source ↗ ClinicalTrials.gov registry/search · Source link recorded; claim verification separate
- NIH/NCBI all-databases search: Cagrilintide + Semaglutide View source ↗ NCBI database/search · Source link recorded; claim verification separate
- PubChem / NIH compound record search: Cagrilintide + Semaglutide View source ↗ PubChem database/search · Source link recorded; claim verification separate
